Cargando…
Myotoxicity of telbivudine in pre-existing muscle damage
OBJECTIVES: It is unknown if telbivudine causes muscle damage only in patients with pre-existing muscle pathology. CASE REPORT: A 27 yo male of African origin received telbivudine for hepatitis B during 3 months. Three weeks after initiation of the drug he developed myalgia, and tiredness. Creatine-...
Autores principales: | Finsterer, Josef, Ay, Leyla |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2998482/ https://www.ncbi.nlm.nih.gov/pubmed/21083916 http://dx.doi.org/10.1186/1743-422X-7-323 |
Ejemplares similares
-
Nelarabine Associated Myotoxicity and Rhabdomyolysis
por: Haider, Mahnur, et al.
Publicado: (2015) -
Myotoxic drugs and immunodeficiency may contribute to the poor outcome of COVID-19 patients with myotonic dystrophy
por: Finsterer, J.
Publicado: (2020) -
Pharmacogenetics of Statin-Induced Myotoxicity
por: Kee, Ping Siu, et al.
Publicado: (2020) -
Two cases of telbivudine-induced myopathy in siblings with chronic hepatitis B
por: Kim, Eun Hye, et al.
Publicado: (2013) -
Phenotype Standardization for Statin-Induced Myotoxicity
por: Alfirevic, A, et al.
Publicado: (2014)